Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent
Authors:
Open Access
- 31 August 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 2334-2347
Abstract
Based on the obtained SARs, further structural optimisation of compound BC2021-104511-15i was conducted in this investigation, and totally ten novel quinoline derivates were designed, synthesised and optimised for biological activity. Among them, compound 10a displayed significant in vitro anticancer activity against COLO 205 cells with an IC50 value of 0.11 μM which was over 90-fold more potent than that of Regorafenib (IC50>10.0 μM) and Fruquintinib (IC50>10.0 μM). Furthermore, compound 10a exhibited over 90-fold selectivity towards COLO 205 relative to human normal colorectal mucosa epithelial cell FHC cells. Flow cytometry study demonstrated that compound 10a could induce apoptosis in COLO 205 cells, however, it could not induce cell cycle arrest in COLO 205 cells. The results of preliminary kinase profile study showed that compound 10a was a potential HGFR and MST1R dual inhibitor, with IC50 values of 0.11 μM and 0.045 μM, respectively.Keywords
Funding Information
- Science and Technology Projects of Guizhou Province
This publication has 29 references indexed in Scilit:
- Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-MetJournal of Medicinal Chemistry, 2013
- Progress in cancer therapy targeting c-Met signaling pathwayArchives of Pharmacal Research, 2012
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitroMolecular Cancer Therapeutics, 2010
- Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon CarcinomaJournal of Biological Chemistry, 2009
- Invasive growth: a MET-driven genetic programme for cancer and stem cellsNature Reviews Cancer, 2006
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2005
- Critical Evaluation of Current Treatments in Metastatic Colorectal CancerThe Oncologist, 2005
- Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinaseCarcinogenesis, 2003
- Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potentialOncogene, 2003